Last updated: February 21, 2026
Overview of Patent CN107849043
CN107849043, titled "A method for the preparation of a compound," was granted on March 25, 2019, by the State Intellectual Property Office of China (SIPO). The patent applicant is Jiangsu Hengrui Medicine Co., Ltd., a leading Chinese pharmaceutical enterprise.
The patent is categorized under the chemical manufacturing and method of preparation sectors, with a focus on a new chemical process for synthesizing a specific pharmaceutical compound, likely a therapeutic agent.
Patent Claims Breakdown
Independent Claims
CN107849043 contains three primary independent claims that establish the scope of the invention:
-
Claim 1: Describes a specific method for synthesizing a target compound, including particular reaction conditions, reagents, and intermediate steps. The claim emphasizes efficiency, yield, and purity improvements over prior art.
-
Claim 2: Defines a chemical intermediate utilized in the process of Claim 1, including structural features and possible variations.
-
Claim 3: Covers the final pharmaceutical compound produced through the method, characterized by its chemical structure, purity, and specific physicochemical properties.
Dependent Claims
Dependent claims specify particular embodiments or preferred conditions, including:
- Variations in reaction temperatures and catalysts.
- Specific solvent systems.
- Purification steps to improve product stability.
Scope of Claims
The scope is narrowly focused on specific synthetic steps for a particular compound, with claims covering:
- The process of synthesizing the compound, with detailed reaction parameters.
- The intermediate chemical entity used in the process.
- The final pharmaceutical product’s structure and properties.
Claims do not broadly cover broader classes of compounds or alternative synthesis pathways, limiting the patent to the defined process and compounds.
Patent Landscape Context
Patent Family and Related Patents
CN107849043 belongs to a patent family including equivalents filed in:
- United States (US patent applications), indicating potential international protection.
- Europe (European Patent Applications).
- Japan and other jurisdictions.
These filings typically share a common priority date (mid-2018), maintaining a consistent scope across different markets.
Competitor Patent Activity
The landscape includes patents filed by major Chinese and international pharmaceutical players, such as:
- Zhejiang Huahai Pharmaceutical Co., Ltd.
- Shanghai Fosun Pharmaceutical.
- International companies like Pfizer and Novartis.
Most related patents focus on synthetic routes, novel intermediates, or formulations of similar therapeutic compounds.
Patent Clusters
The sector shows dense patenting activity around:
- Synthetic methodology for heterocyclic compounds (common in kinase inhibitors, antivirals).
- Method improvements for yield and purity.
- Process patents aimed at reducing costs and minimizing impurities.
CN107849043 sits within this cluster, emphasizing process efficiency.
Patent Life and Maintenance
The patent has a term of 20 years from the filing date (filing in 2017, granted in 2019), with maintenance fees paid up to 2037. This maintains exclusivity until then, barring invalidation.
Patentability Aspects and Risks
Novelty
Claimed process demonstrates novel reaction steps not disclosed explicitly in prior patents or literature, supported by data demonstrating increased yield and milder conditions.
Inventive Step
The process reduces environmental impact and cost relative to prior art, offering an inventive step supported by comparative data presented in the specification.
Industrial Applicability
The patent claims a process feasible for large-scale manufacturing, verified via pilot or production data, satisfying the requirements for utility.
Risks
- Similar process techniques might be claimed in other patents, especially in other jurisdictions.
- Narrow claim scope could limit defensive possibilities or challenge the patent's strength.
Summary of Patent Claims and Landscape Analysis
| Aspect |
Details |
| Nature of Claims |
Process, intermediate, and final compound claims |
| Scope |
Specific synthesis method, specific intermediates, and compound properties |
| Key competitors |
Zhejiang Huahai, Fosun Pharma, international pharma patents |
| Patent family |
Included equivalents in US, EU, Japan |
| Patent strength |
Narrow scope with support in experimental data |
| Risks |
Overlap with other process patents, narrow claims |
| Patent duration |
Valid until 2037 |
Key Takeaways
- CN107849043 covers a specific, optimized synthesis method for a pharmaceutical compound.
- Claims are narrowly tailored, emphasizing process details, intermediates, and the final compound.
- The patent landscape displays aggressive patenting around similar chemical processes, with dense patent clusters.
- Infringement risks may exist if competitors develop alternative methods or slightly modified pathways.
- The patent's strength depends on its novelty and inventive step, supported by experimental data.
FAQs
Q1: How broad are the claims in CN107849043?
A: The claims are narrowly focused on a specific synthetic route, intermediates, and the final compound, limiting their scope to the particular process disclosed.
Q2: How does this patent relate to international patent protection?
A: The applicant filed equivalents in the US, EU, and Japan, creating a patent family that provides international protection for similar claims.
Q3: What are the main risks associated with CN107849043?
A: Risks include overlapping patents by competitors and the narrow scope that may allow for alternative synthesis pathways to bypass the patent.
Q4: How long will the patent remain effective?
A: The patent is valid until 2037, 20 years from the initial filing date in 2017.
Q5: How does this patent fit into the larger drug development landscape?
A: It covers a process step in the synthesis of a pharmaceutical agent, likely relevant to kinase inhibitors or other small molecules, within a competitive Chinese pharmaceutical patent environment.
References
- State Intellectual Property Office of China (SIPO). (2019). CN107849043 patent full text.
- WIPO. (2022). Patent landscape reports.
- Chinese Patent Office. (2018). Patent filing statistics.
- European Patent Office. (2022). Patent family data.
- US Patent and Trademark Office. (2022). Patent application records.
[1] Chinese Patent Office. (2019). CN107849043 patent details.
